| Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trial. | |
| | |
MedLine Citation:
|
PMID: 10178659 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The cost effectiveness of early treatment with lisinopril in acute myocardial infarction (MI) was estimated using survival and cost data gathered prospectively during the hospitalisation of the overall population of patients enrolled in the third study of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI-3), which assessed the efficacy of early (within 24 hours) treatment with an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) for 6 weeks in a group of 19,394 relatively unselected patients with acute MI. A statistically significant reduction in 6-week mortality was achieved among patients treated with lisinopril when compared with patients allocated to the control group (absolute reduction in mortality: 7.5 +/- 3.6 lives saved per 1000 treated patients). The comparative cost-effectiveness ratio for the use of lisinopril, expressed as cost per additional survivor among patients randomised to receive lisinopril, was $US2080 per life saved (1993 values). The sensitivity analysis conducted to examine the effects of varying the estimated absolute reduction in mortality throughout its 95% confidence interval, which ranged from 14.6 to 0.4 lives saved per 1000 treated patients, showed that the cost-effectiveness ratios consequently vary from $US1121 to $US40,910 per life saved. The cost effectiveness of early treatment with lisinopril of a relatively unselected population of patients with acute MI compares very favourably with that of other therapies judged to be worthwhile by the medical community. |
| | |
Authors:
|
M G Franzosi; A P Maggioni; E Santoro; G Tognoni; E Cavalieri |
Related Documents
:
|
19850559 - Pregnancy-associated plasma protein-a is an independent short-time predictor of mortali... 12887069 - The influence of measured versus assumed uptake of oxygen in assessing pulmonary vascul... 20479639 - The effect of chronic kidney disease on fibrin clot properties in patients with acute c... 20467149 - Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. 19327309 - Comparative evaluation of glasgow coma score and gag reflex in predicting aspiration pn... 10073609 - Prevalence and clinical outcome associated with preexisting malnutrition in acute renal... 20308879 - Characteristics and outcome of patients with acute coronary syndrome and normal or near... 17119339 - Urinary retention: a cause of hyponatremia? 23544809 - The impact of cystic fibrosis on the immunologic profile of pediatric patients. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: PharmacoEconomics Volume: 13 ISSN: 1170-7690 ISO Abbreviation: Pharmacoeconomics Publication Date: 1998 Mar |
Date Detail:
|
Created Date: 1998-05-28 Completed Date: 1998-05-28 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9212404 Medline TA: Pharmacoeconomics Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 337-46 Citation Subset: T |
Affiliation:
|
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. franzosi@irfmm.mnegri.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
economics*,
therapeutic use Cardiotonic Agents / economics*, therapeutic use Cost-Benefit Analysis Humans Italy Lisinopril / economics*, therapeutic use Myocardial Infarction / drug therapy, economics* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiotonic Agents; 83915-83-7/Lisinopril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men...
Next Document: Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-t...